Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2015 Financial Results and Investor Teleconference for November 12th

Conference Call to Occur at 5:00PM ET That Day

HOLLISTON, Mass.--()--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, will announce results of its third quarter ended September 30, 2015 and business update after market trading hours on Thursday, November 12, 2015. A conference call to discuss the company’s third quarter results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.

Participating in the call will be Jim McGorry, Chief Executive Officer, Saverio La Francesca, M.D., Executive Vice President and Chief Medical Officer and Tom McNaughton, Chief Financial Officer, of HART.

Investors can access the live conference call by dialing the following phone numbers: toll-free 877-407-8293, or international: 201-689-8349, and referencing Harvard Apparatus Regenerative Technology, Inc. An audio webcast will also be available at http://public.viavid.com/index.php?id=117087.

If you are unable to listen to the live conference call, a replay will be available within approximately 3 hours from the end of the call through 11:59pm ET on November 19, 2015 and will be accessible by dialing toll-free 877-660-6853, or toll/international 201-612-7415, and referencing conference ID “13624147”. The replay will also be made available at the web link above and on the company’s web site, www.harvardapparatusregen.com.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes bioengineered organs for life-threatening conditions. Our technology platform is to be used to restore the function of the airways and the esophagus. Our HART-Trachea technology has been used in several human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Contacts

Harvard Apparatus Regenerative Technology, Inc.
Jim McGorry, 774-233-7320
CEO
jmcgorry@hartregen.com
or
Tom McNaughton, 774-233-7321
CFO
tmcnaughton@hartregen.com

Release Summary

HART will announce results of its third quarter ended September 30, 2015 and business update after market trading hours on Thursday, November 12, 2015

Contacts

Harvard Apparatus Regenerative Technology, Inc.
Jim McGorry, 774-233-7320
CEO
jmcgorry@hartregen.com
or
Tom McNaughton, 774-233-7321
CFO
tmcnaughton@hartregen.com